Molecular Detection and Typing of Human Papillomaviruses in Paraffin-Embedded Cervical Cancer and Pre-Cancer Tissue Specimens

Mahmoodi, Pezhman; Motamedi, Hossein; Shapouri, Masoud Reza Seyfi Abad; Shehni, Mahjabin Bahrami; Kargar, Mohammad

doi:10.17795/ijcp-3752

Cited by 4 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cervical cancer is ranked as the second most common cancer in women worldwide (18,19). A most important feature of cervical cancer is the high mortality rate, which is mainly attributed to the lack of effective therapies for women with high-grade cervical cancer (20).…”

Section: Discussionmentioning

confidence: 99%

Allicin suppresses the migration and invasion in cervical cancer cells mainly by inhibiting NRF2

Zhang

Yang

2018

Exp Ther Med

View full text Add to dashboard Cite

Emerging evidence has demonstrated the antitumor activity of allicin in various tumors. However, little study has been carried out on the functional role of allicin in cervical cancer. Our data showed that allicin suppressed cervical cancer cell viability in a time- and dose-dependent manner. Allicin treatment could reverse H2O2-induced reactive oxygen species accumulation. Meanwhile, levels of glutathione and superoxide dismutase were increased, but malondialdehyde was decreased after allicin incubation for 48 h. Furthermore, TUNEL staining showed that H2O2 treatment induced cell apoptosis, but allicin treatment could decrease cell apoptosis. Western blot assay showed that allicin could suppress the expression of nuclear factor erythroid 2-related factor 2 (NRF2) and heme oxygenase 1. We also showed that NRF2 prompted SiHa cell proliferation and reduced SiHa cell apoptosis. More importantly, allicin-inactivated phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling could be partially reversed by overexpressing of NRF2. We also evaluated cell apoptosis in SiHa cells transfected with plasmid NRF2. Our data showed that allicin-induced cell apoptosis (43.5±3.8%) could largely be abolished by upregulation of NRF2 (12.3±2.08%). In summary, our data showed allicin was effective in suppressing the malignant phenotype of cervical cancer cells mainly by inhibiting the expression of NRF2, showing the potential clinical benefits of allicin in cervical cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Allicin suppresses the migration and invasion in cervical cancer cells mainly by inhibiting NRF2

Zhang

Yang

2018

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Higher prevalence rates of HPV were reported in studies carried out in Croatia (92-7%) [11], USA (91.3%) [16], India (93.0%) [17], Thailand (94.8%) [18], Malawi (97.0%) [19], South Africa (92.1%) [20] and Ibadan Nigeria (90.7%) [21]. However, relatively low HPV prevalence rates were also observed in Poland (53.0%) [22], Khuzestan Iran (43.3%) [23] and Tehran Iran (49.0%) [24]. These differences in the reported prevalence rates of HPV in cervical cancer tissues could be attributed to several factors among which include geographical variations [10, 12, 13], quality and quantity of biological specimens [25-28], methods of DNA extraction and sensitivity [29], and specificity of HPV detection methods [27, 28, 30-32].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria

Kabir¹,

Bukar²,

Nggada³

et al. 2019

Pan Afr Med J

View full text Add to dashboard Cite

IntroductionCervical cancer is the commonest gynaecological malignancy and the second most common cancer among women worldwide. Several epidemiological, clinical and molecular studies have strongly implicated oncogenic high-risk human papillomavirus infection in the aetiopathogenesis of cervical cancer. The objectives of this study were to determine the cervical HPV prevalence and genotype distribution in cervical cancer in Maiduguri, Nigeria.MethodsThis was a descriptive and retrospective study. Sixty-three archived paraffin-embedded tissue blocks with confirmed diagnoses of cervical cancer during the study period (2013-2015) were retrieved and examined. The procedure included deparaffinization of tissue samples, DNA extraction, PCR, gel electrophoresis, and HPV genotyping by reverse hybridization line probe assay.ResultsSixty-three cervical cancer cases were subjected to genomic DNA extraction and HPV-DNA detection by PCR. Fifty-eight samples showed PCR positivity while 5 samples were PCR negative. HPV-specific DNA was detected in 44 of the 58 PCR-positive samples and thus the prevalence was 69.8%. Ten different high-risk HPV genotypes were detected. Both single and multiple high-risk HPV infections were observed. The most prevalent type of the human papillomavirus detected was HPV16.ConclusionHPV-DNA was prevalent in majority of the examined cervical cancer tissues and that HPV16, HPV18, HPV45, HPV51 and HPV52 were the predominant HPVs detected in both single and multiple HPV infections. The results of this study and further studies will provide more detailed information about HPV and may contribute significantly to the prevention of cervical cancer through primary high-risk HPV testing and HPV vaccination against the oncogenic viruses.

show abstract

“… 30 Therefore, it is important to identify new molecular markers of CC to facilitate more accurate prediction of clinical outcomes and prescription of effective treatment. 31 …”

Section: Discussionmentioning

confidence: 99%

PBX3 is associated with proliferation and poor prognosis in patients with cervical cancer

Sun

Liu

et al. 2017

OTT

View full text Add to dashboard Cite

Pre-B-cell leukemia homeobox 3 (PBX3) is upregulated in various malignancies; however, the role of PBX3 in cervical cancer (CC) is unknown. The purpose of this study was to explore the expression characteristics, clinicopathological significance, and molecular biological function of PBX3 in CC. The expression levels of PBX3 were analyzed in CC cell lines and tumor specimens by real-time polymerase chain reaction (RT-PCR), Western blotting, and immunohistochemical staining. The clinicopathological characteristics associated with PBX3 expression were evaluated. An RNA interference approach was employed to suppress PBX3 expression in CC in vitro and in vivo, determine its role in cell proliferation and analyze its molecular function. We found that PBX3 expression was significantly upregulated in CC cell lines and clinical specimens compared with normal cells and adjacent nontumorous cervical tissues. PBX3 was an independent predictive factor of poor prognosis, and its expression was correlated with tumor diameter, pathological grading, lymph node metastasis, invasion depth, vascular invasion, and clinical stage of CC. Multivariate analysis suggested that PBX3 expression may represent an independent prognostic indicator of the survival of CC patients. CC patients with high PBX3 expression exhibited reduced overall survival compared with those with low PBX3 expression. Additionally, stable downregulation of PBX3 expression in CC cell lines suppressed cell proliferation and decreased p-AKT protein expression levels in vitro. Similarly, in vivo assays demonstrated that PBX3 downregulation in CC cells markedly inhibited tumor size and weight. Overall, we demonstrated that PBX3 can promote CC cell proliferation via the AKT signaling pathway and that it may serve as a prognostic marker. Our data indicate that inactivation of PBX3 may be an effective clinical treatment for CC.

show abstract

Molecular Detection and Typing of Human Papillomaviruses in Paraffin-Embedded Cervical Cancer and Pre-Cancer Tissue Specimens

Cited by 4 publications

References 35 publications

Allicin suppresses the migration and invasion in cervical cancer cells mainly by inhibiting NRF2

Allicin suppresses the migration and invasion in cervical cancer cells mainly by inhibiting NRF2

Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria

PBX3 is associated with proliferation and poor prognosis in patients with cervical cancer

Contact Info

Product

Resources

About